In presurgery treatment of early-stage cancer, there has been much debate over whether the absence of cancer in surgically removed tissue serves as a good indicator of whether treatment will preven | With a new analysis of Opdivo’s first-in-class win in presurgery lung cancer, Bristol Myers Squibb is drawing a widely …Click the link below to read more.
#Conducting performance reviews virtually